Condition: Breast Cancer · Sponsor: Endomagnetics Ltd.
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast
This description comes directly from the study's public registry record.
Matt Womack, Dr · +447851247439 · mwomack@endomag.com
Tanja Odeneg, Dr · +441223652604 · todeneg@endomag.com
Always discuss trial participation with your own doctor first.
| Marienhospital Bottrop GmbH | Bottrop, Germany | Recruiting |
| AGAPLESION Markus Frankfurter Diakonie Kliniken gGmbH | Frankfurt, Germany | Recruiting |
| Technical University Munich | Munich, Germany | Not Yet Recruiting |
| Guy's Hospital | London, United Kingdom | Recruiting |
| Royal Marsden Hospital | London, United Kingdom | Recruiting |
| University Hospital South Manchester | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05142787